Search Results for "Alnylam"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
ATTR Diagnostic and Staging Tools
This deck highlights diagnostic and staging tools for assessing patients with ATTR.
This deck highlights diagnostic and staging tools for assessing patients with ATTR.
Disease Burden and Unmet Need in Hypertension
This slide deck provides a brief overview of uncontrolled hypertension in the US, the associated risks, and the role of tonic blood pressure control.
This slide deck provides a brief overview of uncontrolled hypertension in the US, the associated risks, and the role of tonic blood pressure control.
Hereditary ATTR Amyloidosis: A Closer Look at the V122I Variant External
V122I is the most common variant of hATTR amyloidosis in the United States and is most prevalent in patients of African American descent. Compared to other variants, patients with the V122I variant experience significant disease burden and poorer outcomes.
V122I is the most common variant of hATTR amyloidosis in the United States and is most prevalent in patients of African American descent. Compared to other variants, patients with the V122I variant experience significant disease burden and poorer outcomes.
The Unpredictable Progression of PH1
This handout details the potential progressive decline of kidney function in PH1, which mostly results in end-stage kidney disease.
This handout details the potential progressive decline of kidney function in PH1, which mostly results in end-stage kidney disease.